Publications by authors named "C Granier"
Background: Immune ageing complicates cancer treatment in older individuals. While immunotherapy targeting the PD-1/PD-L1 pathway can reinvigorate T cells, these cells tend to become senescent with age. This study investigates different CD8 T cell subsets usually associated with senescence, in cancer patients over 70 years old who are undergoing anti-PD-1/PD-L1 immunotherapy, and examines the relationship between these senescent cells and prior chemotherapy exposure.
View Article and Find Full Text PDFArticle Synopsis
- Biomass burning (BB) produces harmful gases and particles that affect air quality and climate, but scientists haven't focused much on chlorine emissions from this process.
- A study from 2001 to 2018 found that Asia released a lot of chlorine from BB, especially China, Myanmar, and India, and that this can change with farming practices.
- The research showed that burning biomass increases chlorine levels in the air, which affects other important chemicals, making BB a bigger player in air pollution than we thought.
Article Synopsis
- Ageing affects immune responses, increasing the risk of infections like COVID-19 in older adults, particularly through factors related to cytotoxic T cells and chronic inflammation.* -
- In a study of 104 patients over 70, severe COVID-19 correlated with higher levels of specific cytokines (like GM-CSF and IL-1β) and changes in CD8 T cell populations, including more terminally differentiated cells and fewer stem cell-like memory cells.* -
- The findings suggest that certain cytokines are key indicators of COVID-19 severity in older patients and emphasizes the need for tailored care approaches based on these immune changes in this age group.*
Background: There is increased evidence that the effects of stem cells can mostly be duplicated by administration of their secretome which might streamline the translation towards the clinics.
Methods: The 12-patient SECRET-HF phase 1 trial has thus been designed to determine the feasibility and safety of repeated intravenous injections of the extracellular vesicle (EV)-enriched secretome of cardiovascular progenitor cells differentiated from pluripotent stem cells in severely symptomatic patients with drug-refractory left ventricular (LV) dysfunction secondary to non-ischemic dilated cardiomyopathy. Here we report the case of the first treated patient (baseline NYHA class III; LV Ejection Fraction:25%) in whom a dose of 20 × 10 particles/kg was intravenously infused three times three weeks apart.
This phase III study assessed the efficacy/safety/antiviral activity/pharmacokinetics of bemnifosbuvir, a novel, oral nucleotide analog to treat COVID-19. Outpatient adults/adolescents with mild-to-moderate COVID-19 were randomized 2:1 to bemnifosbuvir/placebo. Time to symptom alleviation/improvement (primary outcome), risk of hospitalization/death, viral load and safety were evaluated.
View Article and Find Full Text PDF